SCHEMBL3700453

SCHEMBL3700453

C[C@@H](C[C@@H](Cc1ccc(-c2cccc(Cl)c2)cc1)NC(=O)CCC(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MME P08473 13/20 1.00
MMEL1 Q495T6 4/20 1.00
ACE P12821 5/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3709244 1.00 MME (1.00) MMEMMEL1ACE
SCHEMBL14890350 0.89 MME (1.00) MMEMMEL1ACE
SCHEMBL3714794 0.89 MME (0.80) MMEMMEL1ACE
SCHEMBL3710898 0.89 MME (0.80) MMEMMEL1ACE
Lbq-657 SCHEMBL391633 0.89 MME (1.00) MMEMMEL1ACE
Lbq-657 SCHEMBL489122 0.89 MME (1.00) MMEMMEL1ACE
Lbq-657 SCHEMBL7433849 0.89 MME (1.00) MMEMMEL1ACE
Lbq-657 SCHEMBL9565416 0.89 MME (1.00) MMEMMEL1ACE
Lbq-657 SCHEMBL1908575 0.89 MME (1.00) MMEMMEL1ACE
SCHEMBL2878447 0.86 MME (1.00) MMEMMEL1ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673974-B2 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors NOVARTIS AG (CH) 2014-03-18 US disclosed
US-8673974-B2 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors NOVARTIS AG (CH) 2014-03-18 US disclosed
US-8673974-B2 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors NOVARTIS AG (CH) 2014-03-18 US disclosed
EP-2640690-A1 SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS Novartis AG (CH) 2013-09-25 EP disclosed
WO-2012065956-A1 SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2012-05-24 WO disclosed
WO-2012065956-A1 SUBSTITUTED AMINO BISPHENYL PENTANOIC ACID DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2012-05-24 WO disclosed
US-20120122977-A1 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors NOVARTIS AG (CH) 2012-05-17 US disclosed
US-20120122977-A1 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors NOVARTIS AG (CH) 2012-05-17 US disclosed
US-20120122977-A1 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors NOVARTIS AG (CH) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122977-A1 Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors REN, MME, AGTR1 MME 2/4885MMEL1 545/4885ACE 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.